ImmuCell Corp
NASDAQ:ICCC
ImmuCell Corp
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 60 full-time employees. The firm is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. The company manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. The company expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The firm is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 60 full-time employees. The firm is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. The company manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. The company expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The firm is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
